TC Biopharm’s shares are trending higher in pre-market trading this morning. Up almost 70% trading around $1.07 on heavy volume and more than 16,000 trades.

May 26, 2022

TC Biopharm (Holdings) PLC (“TC Biopharm” or the “Company”) (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced today announced the formation of a scientific advisory board (SAB) to advance its gamma-delta T cell therapy, OmnImmune, for the treatment of Acute Myeloid Leukemia (AML).

Company recently announced an offering.

Commercial satellite company lands Government contract and sends shares soaring. Read about this 100% mover with record volume and 346,000 trades.

TCBP Chart by TradingView

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.